Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Durham, North Carolina 27710


Purpose:

This is a pilot study to test feasibility of collection, preparation and infusion of a baby's own (autologous)umbilical cord blood in the first 14 days after birth if the baby is born with signs of brain injury.


Study summary:

The purpose of this pilot study is to evaluate the safety and feasibility of infusions of autologous (the patient's own)umbilical cord blood cells in term gestation newborn infants with hypoxic-ischemic encephalopathy. For this study, infants who have signs of moderate to severe encephalopathy at birth whose mothers have previously consented to providing cord blood cells for the Carolinas Cord Blood Bank or other public or private bank that uses accepted standards for collection and handling of cells, or provided verbal consent for cord blood collection for the possibility of their baby's participation in this trial, can receive their own cord blood cells if an adequate number of cells that meet Carolinas Cord Blood Bank Quality standards are available in the first 14 postnatal days. Study activities also include serial blood draws concurrent with clinically indicated blood draws with a total volume of no more than 5 milliliters (1 teaspoon) from all study related tests. Babies will be followed for neurodevelopmental outcome at 4 - 6 and 9 - 12 months at Duke's Special Infant Care Clinic. MRI's will be obtained per clinical routine and results will be analyzed and described in study reports.


Criteria:

Inclusion Criteria: - Mothers must have consented for cord blood collection at delivery - cord blood must be available for extraction of stem cells. - >34 weeks gestation - cord or neonatal pH<7.0 or base deficit>16 milliequivalents per liter (mEq/L) or history of acute perinatal event - either a 10 minute Apgar < 5 or continued need for ventilation. - All infants must have signs of encephalopathy within 6 hours of age. Exclusion Criteria: - Inability to enroll by 14 days of age. - Presence of known chromosomal anomaly. - Presence of major congenital anomalies. - Severe intrauterine growth restriction (weight <1800g) - Infants in extremis for whom no additional intensive therapy will be offered by attending neonatologist. - Parents refuse consent. - Attending neonatologist refuses consent. - Failure to collect the infant's cord blood and/or laboratory unable to process cord blood.


NCT ID:

NCT00593242


Primary Contact:

Principal Investigator
Charles M Cotten, MD MHS
Duke University


Backup Contact:

N/A


Location Contact:

Durham, North Carolina 27710
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: March 16, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.